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Summary In an attempt to develop an assay to predict patient tumour response to cyclophosphamide (CP),
the feasibility of using a glutathione-targeted assay to assess the in vitro chemosensitivity of tumour cells to
4-hydroperoxylcyclophosphamide (4-OOH-CP), an activated congener of CP, was evaluated. A panel of 19
human and three murine tumour cell lines was used. These consisted of three main categories of tumour types,
viz. ovarian, lung and squamous cell carcinoma. The major finding was that the occurrence of a significant
reduction of tumour cell reproductive capacity was always accompanied by substantial depletion of cellular
glutathione (GSH) content, and vice versa. Plots of % GSH depletion versus clonogenic cell survival
demonstrated highly significant correlation (r=0.90-0.91; P<0.01). It was determined that for in vitro
tumour cell lines, a GSH depletion to 40% of initial content may serve as a cut-off criterion for chemosen-
sitivity to 4-OOH-CP. This degree of GSH depletion is indicative of clonogenic cell survival of approximately
1% (95% confidence limits = 3 x 10-5- 1.6 x 10-2). The relationship between steady state GSH content and
intrinsic sensitivity to 4-OOH-CP was also evaluated. The GSH concentration of the tumour cell lines ranged
from 1.3-21.2 x 10-i8 moles lm-3; chemosensitivity to 4-OOH-CP, in terms of IC99, was in the range of
5.0-87.1IM. A good correlation was observed between these two parameters (r = 0.85, P<0.02). These
results suggest that GSH plays an important role in determining the therapeutic efficacy of 4-OOH-CP in the
treatment of cancer. It is uncertain, however, whether a high tumour steady state GSH content in itself is
sufficient to cause therapeutic failure in patients.
Cyclophosphamide (CP) and its congeners are among the
most efficacious and frequently used agents for the treatment
of human malignancies. The pharmacology and metabolic
fate of CP has been extensively studied and is now relatively
well understood (Sladek, 1987). When given systemically, CP
is metabolised, through hydroxylation by the hepatic mixed-
function oxidases, to 4-hydroperoxycyclophosphamide (4-
OH-CP), a 'transport' form of CP which exists in equilibrium
with its ring-opened tautomer aldophosphamide (AP). Gluta-
thione (GSH) can participate in conjugative reactions at two
separate locations in the cyclophosphamide metabolic path-
way that may exert considerable influence on the eventual
cytotoxicity of the cytotoxic agent (see Figure I of the
accompanying paper (Lee, 1990) and others (Draeger et al.,
1976; Gurtoo et al., 1981)). (1) GSH reacts with AP to form
4-OH-CP and shifts the tautomerism pseudo-equilibrium
between 4-OH-CP and aldophosphamide (AP) in favour of
the former tautomer (Draeger et al., 1976; Lee, 1990). (2)
GSH binds irreversibly to the toxic metabolites of 4-OH-CP,
in particular acrolein (Gurtoo et al., 1981). Because of these
reactions, exposure of cells to 4-OH-CP may lead to deple-
tion of endogenous GSH if the combined rates of the con-
jugation reactions exceed the rate of GSH recovery. In fact, a
number of studies, all using high and therefore toxic doses of
CP, have already shown that CP depletes cellular GSH level
in vivo (Adams et al., 1986; Carmichael et al., 1986) and in
vitro (Crook et al., 1986). Recently, in a series of experiments
in which both GSH status and cytotoxicity were determined
in the same tumour cell population, we observed that toxic
concentrations of 4-OOH-CPt severely depleted tumour cells
of GSH whereas nontoxic concentrations of 4-OOH-CP pro-
duced no such effect (Siemann et al. in preparation). Further-
more, a tumour cell type (KHT) highly susceptible to GSH
depletion by 4-OOH-CP was also found to be highly sensitive
to this agent while a tumour cell line (A549) resistant to
GSH depletion by 4-OOH-CP was shown also to be refrac-
tory to the drug's cytotoxic effects. The present study was
therefore designed to: (1) establish in detail the relationship
between 4-OOH-CP induced GSH depletion and cytotoxicity
and (2) determine whether measurements of the extent of
GSH depletion induced by clinically relevant concentrations
of 4-OOH-CP can be used to predict for tumour response to
this anticancer agent.
Materials and methods
Cell culturing
Three major categories of human tumour cell lines were used
in this study: ovarian, lung and squamous cell carcinomas.
The ovarian cell lines, except SKOV-3, CaOV-3 and NIH:
OVCAR-3, were established from biopsy specimens (Lee et
al., 1989). SKOV-3, CaOV-3 and NIH:OVCAR-3 were
obtained from the American Type Culture Collection. The
small cell lung line POC was received from Dr P. Twenty-
man. The other lung lines were obtained from Dr J. Mitchell
courtesy of Dr J. Minna. Three epidermoid cell lines were
also used in this study. They were HEp3 derived from a
metastatic buccal mucosa carcinoma (Toolan, 1954), A431
derived from a vulva carcinoma (Giard et al., 1973), and
ME180 derived from a cervix carcinoma (Sykes et al., 1970).
Limited studies with the rodent KHT sarcoma cell line (Kall-
man et al., 1967) were performed. Culture conditions, growth
characteristics and plating efficiency for the human tumour
cell lines are listed in Table I. All nutrient media and sera
were obtained from Gibco Laboratories (Grand Island, NY).
Cell cultures were maintained at 37'C under an atmosphere
of 5% C02/95% air. All cell lines, except POC, grew as
monolayers and were routinely subcultured every 3 to 4 days
with standard trypsinisation procedures using Worthington's
trypsin (Worthington Biochemical Corp, New Jersey, USA).
Clonogenic assays were performed with exponentially grow-
ing cells 2 to 3 days after seeding.
t4-OOH-CP gives rise rapidly to 4-OH-CP following dissolution
without any enzymic involvement and may be regarded as equivalent
to 4-OH-CP pharmacologically (Sladek, 1987). 4-OOH-CP is the
preferred 'activated' cyclophosphamide for routine use only because
of its higher stability in crystalline state and easier synthesis.
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Figure 1 Clonogenic cell survival of three main categories of human tumour cell lines following treatment with various
concentrations of 4-OOH-CP for 3 h. Each datum point is the mean surviving fraction determined from the colony counts of
10- 15 plates. Standard errors are for all instances < 10% of the mean. Error bars when shown, are + 1 s.d. Results are from at
least three repeat experiments.
Table I Characteristics and treatment histories of the human tumour cell lines investigated
Tumour FCS Ploidy TD CFE Mean cell
Cell lines types Medium (%) Ratio (h) (%) Prior treatment volume (fun3)
Human ovarian
ATW OVAC a-MEM 10 2.4 48 9 C,A,P 5,600
PEA OVAC a-MEM 10 1.4 72 14 C,A,P 2,700
GRA OVAC a-MEM 10 1.5 96 25 None 3,400
MLS OVAC a-MEM 10 1.8 30 72 C,A,P,F,Mx,Tf 2,800
SKA OVAC a-MEM 10 1.8 48 37 C,A,P.F,Mx,Tf 4,500
SAU OVAC a-MEM 10 1.8 58 38 None 8,500
OW-I OVAC a-MEM 10 2.1 24 85 C,A,P,M,Mx 2,500
SKOV-3 OVAC a-MEM 10 2.2 48 26 T 2,700
CaOV-3 OVAC a-MEM 10 2.0 48 6 C,A,F 5,000
NIH:OVCAR-3 OVAC a-MEM 10 1.9 88 15 C,A,P 5,400
Human lung
A549 LAC RPMI-1640 10 - 24 60 N.A. 2,500
NCI-H520 LSqC RPMI-1640 10 - 24 75 None 2,600
NCI-H226 LSqC RPMI-1640 10 - 24 15 None 4,550
NCI-H157 LCLC RPMI-1640 10 - 24 55 None 3,300
POC SCLC RPMI-1640 10 96 10 N.A. 970
Human epidermoid
A431 EpCa D-MEM 10 1.9 26 55 None 3,000
HEp3 EpCa F-12 20 1.9 27 40 None 4,400
ME180 EpCa F-12 10 1.5 28 70 Rx 1,900
Human breast
SKBR3 BCa RPMI-1640 10 - 48 12 N.A. 2,900
H50578 BCa RPMI-1640 10 - 54 15 N.A. 3,100
Rodent
KHT MFSa a-MEM 10 1.9 20 55 None 1,800
CHO/AUXBI CHO F-10 10 - 12 100 None 1,300
CHCR5 CHO F-10 10 - 18 100 Colchicine 1,600
OVAC, ovarian adenocarcinoma; LAC, lungadenocarcinoma; LSqC, lungsquamous carcinoma; LCLC,
large cell lung cancer; SCLC, small cell lung cancer; EpC, epidermoid squamous carcinoma; BCa, breast
carcinoma; MFSa, murine fibrosarcoma; CHO, Chinese hamster ovary; FCS, foetal calf serum; TD,
population doubling time; CFE, colony-forming efficiency. Therapy received before establishment of cell
line: c, cyclophosphamide; A, adriamycin; P, cisplatin; F, 5-fluorouracil; M, melphalan; Mx, methotrexate;
Tf, tamoxifen; T, thiotepa; N.A., information not available.
Drug preparation and treatment
For drug treatment, cells were trypsinised and a single-cell
suspension at 2.5 x IO' cells ml-' in complete medium was
placed in a type I vial at 37°C and continuously gassed with
a 5% C02/95% air gas mixture as previously described
(Whillans & Rauth, 1980; Siemann et al., 1989). Cells were
allowed to equilibrate at these conditions for 30 min prior to
drug exposure. Drug treatment was for a 3 h period.
4-hydroperoxycyclophosphamide (4-OOH-CP) and deschlo-
ro-4-hydroperoxycyclophosphamide (deschloro-4-OOH-CP)
were generous gifts from Dr R.F. Borch (Department of
Pharmacology, University of Rochester, USA) and Dr P.
Hilgard (ASTA-Werke Bielefeld, FRG). Both agents were
dissolved in phosphate-buffered saline (PBS), pH 7.4, and
10 il of the solution were diluted in 1 ml of culture media,
containing the cell suspension being tested, to obtain the final
concentration.
Clonogenic cell survival assay
At the end of the drug exposure, cells were washed by
centrifugation through 14ml of cold medium for 10 min at
1,000g. The cell pellet was resuspended in complete medium
plus foetal calf serum, and the cells were counted with aTUMOUR SENSITIVITY TO CYCLOPHOSPHAMIDE 219
Coulter Counter (Model ZBI, Hialeah, FL). Various number
of cells were plated in cell culture dishes and 12-18 days
later, depending on the cell line, the dishes were stained with
crystal violet and survival was determined by counting col-
onies having more than 50 cells.
Glutathione analysis
Following and at select times during drug exposure, aliquots
of cells were removed for HPLC analysis of GSH. Soluble
GSH was extracted from cells by homogenisation with 2001l
of 20 mm 5-sulfosalicylic acid. The homogenates were centri-
fuged for 40 s (Eppendorf Microcentrifuge). GSH was deriva-
tised to a fluorescent conjugate by reacting an aliquot
(180pl) of the supernatant with 12jil of N-ethylmorpholine
(0.5 M in 2.0 mM KOH) and 2 Il monobromobimane (50 mM
in acetonitrile, Calbiochem). The reaction mixtures were
immediately vortexed and stored in the dark at 4°C until
analysis.
Cellular GSH concentrations were measured by pair-ion
HPLC as previously described in detail (Lee et al., 1988).
Briefly, GSH was separated on Waters Radial-PAK reversed-
phase bonded octadecylsilane cartridge columns (C18, 8 mm
inner diameter, 5 ltm diameter spherical particles). The
mobile phase consists of 23% acetonitrile in 40 mM ammon-
ium phosphate buffer, pH 7.2, containing 5 mM tetra-butyl-
ammonium hydroxide. The elution condition was isocratic at
a flow rate of 3 ml min' and a total run time of 5 min/
sample.
Results
Clonogenic cell survival
Cell survival curves for the three categories of tumour cell
types, following treatments with various concentrations of
4-OOH-CP in vitro, are shown in Figure 1. These cell lines
had vastly different sensitivities to 4-OOH-CP. The IC50, IC90
and IC99 values ranged from 0.74-25.5, 2.5-56, and 5.0-
87.0 jiM respectively (Table II). Interestingly, most of the cell
lines (four out of five) derived from squamous cell car-
cinomas were resistant to 4-OOH-CP even though none of
them had previously been exposed to chemotherapeutics
(Table I). On the other hand the ovarian tumour cell lines,
some having been previously exposed to cyclophosphamide,
showed a wide spectrum of sensitivities to 4-OOH-CP, rang-
ing from the extremely sensitive (e.g. GRA) to the very
resistant (e.g. SKOV-3). These characteristics are very much
in accordance with the clinical behaviour of these tumour
types to cyclophosphamide treatment.
Cellular GSH content at steady-state
Table II lists the GSH content of all cell lines used. The
experiments were internally controlled such that tumour cells
used for GSH determinations were drawn from the same
pool of cells as those used for chemosensitivity assays. GSH
contents varied markedly with tumour cell line, ranging from
1.3 to 21.2 x 1018 moles jim-3. Normalisation of GSH con-
tents with respect to cell volume was essential because the
different cell types have diverse cell volumes (Table I), the
range being 967-8,500Im3.
The relationship between steady-state GSH level and
clonogenic cell survival
Table II and Figure 2 depict the relationship between the
sensitivity of the various cell lines to 4-OOH-CP, in terms of
IC50, IC90 and IC99, and their steady-state GSH levels. Two
definite conclusions can be drawn from these results. (1)
There appears to be a direct correlation between the GSH
content of a cell type and its resistance to 4-OOH-CP. The
goodness of correlation was dependent on the survival end-
point chosen as the indicator of sensitivity. The greater the
degree of cell kill chosen (e.g. IC90 vis a vis ICW) the better
was the correlation. Thus, progressively higher correlation
coefficients of 0.78, 0.83 and 0.85 were obtained for steady-
state GSH content versus IC50, IC90 and IC99 respectively. (2)
Table II Origin, sensitivity and GSH content of cancer cell lines tested using the
glutathione-targeted drug-sensitivity assay
IC50 Conc. IC90 Conc. IC99 Conc. GSH Content
Cell linesa (AM) (AM) (AM) (x 1018molpm3
Human ovarian ca.
PEA 4.0±0.7 14.0±2.1 28.6±7.2 5.5±0.5
GRA 2.5±0.5 8.0± 1.5 15.6±3.9 6.8±0.7
MLS 7.0± 1.6 16.3±2.5 29.6± 10.3 12.5± 1.0
MLS/CPR 13.8±4.1 34.5±7.2 87.1 ±23.0 16.9± 1.8
MLS/ADRR 10.4± 3.3 26.1 ± 6.5 58.2± 18.7 14.3± 1.5
SKA 18.0±3.0 29.6± 5.3 39.0±9.0 9.2±0.7
SAU 15.0±4.8 28.0±3.5 40.7± 11.8 8.0±0.9
OW-1 3.5±0.8 12.5±2.2 25.0± 5.1 6.8±0.4
SK-OV-3 20.0±4.4 41.5±6.0 71.5± 15.5 18.9± 1.4
Caov-3 2.3±2.9 7.4± 1.6 15.0±3.2 9.0± 1.2
NIH:OVCAR-3 1.1±0.3 4.0±0.5 11.0±2.5 4.12±0.6
Human lung ca.
A549 25.0± 7.0 56.0±6.9 84.0± 19.0 14.4± 1.9
NCI-H520 20.0± 10 49.0± 5.4 78.0± 11.6 13.2±0.7
NCI-H157 1.0±0.2 3.5±0.4 7.0± 1.0 4.3±0.5
NCI-H226 1.5±0.3 4.0±0.7 8.0± 1.2 9.1±0.8
Human epidermoid
A431 25.5±7.8 51.5±9.6 78.0± 14.4 21.3±2.4
HEp3 13.0±4.2 38.0±6.1 73.0±8.1 16.1 ± 1.3
ME-180 16.0±3.9 27.0± 8.8 46.0± 10.9 7.8±0.9
Human breast
SKBR3 3.0±0.7 10.6±2.8 19.5±5.7 7.6±1.1
H50578 5.5± 1.6 15.7±4.4 25.6±4.8 11.1±2.0
Rodent lines
KHT 0.74±0.2 2.50±0.8 5.0±0.8 1.3±0.2
CHO/AUXB1 2.0±0.5 6.5± 1.6 13.0± 3.4 4.70±0.8
CHCR5 4.5±1.2 11.6±3.0 16.5± 5.1 6.91±1.3
aMLS/CPR and MLS/ADRR were cell lines selected from the parent MLS line for
4-OOH-CP and ADR resistance by in vitro exposure to the respective agents.220 F.Y.F. LEE et al.
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Figure 2 The relationship between steady-state cellular GSH content of 21 tumour cell lines (three murine, 18 human) and
chemosensitivity to 4-OOH-CP. Chemosensitivity was expressed in terms of IC5o, IC90 and IC". Error bars represent ± I s.d. Each
datum point is the average of triplicate determinations.
As shown in Figure 2, there was considerable scattering of
the data in the GSH content versus sensitivity plots. Indeed,
it is likely that no correlation between GSH content and
sensitivity to 4-OOH-CP would have been apparent if only a
few cell lines, chosen at random from the 17 reported here,
were studied. It therefore appears that steady-state GSH
content per se cannot serve as an accurate indicator of
cellular sensitivity to 4-OOH-CP.
The effects of4-OOH-CP on cellular GSH content
Incubation of cells with significantly toxic concentrations of
4-OOH-CP invariably led to rapid GSH depletion (compare
Figure 3a, b). The rate of depletion was rapid during the
initial 60 min, but levelled off considerably thereafter.
Recovery of GSH content did not occur during the entire 3 h
incubation period. Similar GSH depletion kinetics have pre-
viously been reported for the KHT murine fibrosarcoma
(Siemman et al., 1989). It should be noted that the loss of
cellular GSH following 4-OOH-CP treatment was not caused
by leakage to the medium as a result of a loss of membrane
integrity. The plasma membrane remained intact following
treatment with concentrations of 4-OOH-CP that caused
severe reduction of clonogenic capacity. As determined by
trypan blue exclusion technique over 95% of cells in all
treatment groups retained the ability to exclude the vital dye.
In addition, deschloro-4-hydroperoxycyclophosphamide, a
vastly less cytotoxic analogue of 4-OOH-CP has been shown
to cause severe GSH depletion at non-toxic concentration
(Lee, 1990). These results are consistent with the accepted
view that the cytotoxic action of 4-OOH-CP resides in its
ability to produce DNA crosslinks (Hilton, 1984). On the
other hand, acrolien, a breakdown product of 4-OOH-CP
released intracellularly is believed to be responsible for the
GSH depleting action (Gurtoo et al., 1981; Lee, 1990).
The relationship between GSH depletion and cellular sensitivity
to 4-OOH-CP
It was initially observed that when cells were treated with
4-OOH-CP, significant cytotoxicity was always accompanied
by significant depletion of GSH content, and vice versa. This
observation led us to question whether or not the degree of
GSH depletion could be used as a convenient predictor of
cellular sensitivity to 4-OOH-CP. A series of internally con-
trolled experiments were performed in which both clonogenic
cell survival and GSH depletion were measured on pooled
cell populations treated with various concentrations of 4-
OOH-CP. Figure 4 summarises the correlative data between
cell survival and GSH depletion for the ovarian cancer cell
lines (panel a) and the lung and squamous carcinoma cell
lines (panel b). Excellent correlations exist between the degree
of GSH depletion and cellular sensitivities to 4-OOH-CP.
The feasibility of using GSH depletion as a predictor for
chemosensitivity is illustrated by the following. At GSH
depletion level of 40% of initial content, the toxicity level
was -1 % cell survival (95% confidence limits = 3 x I0-5
-1.6 x 10-2). This degree of depletion can therefore be used
as the 'cut-off' criterion for sensitivity since cells that were
depleted to 40% of their GSH content, or lower, invariably
suffered substantial cell kill. Thus cell lines that demonstrated
GSH depletion to or beyond the 'cut-off' 40% point with
clinically achievable equivalent concentrations of 4-OOH-CP
may be considered as sensitive, and vice versa. In addition, a
precise definition of sensitivity can be obtained using different
concentrations of 4-OOH-CP, as illustrated by Figure 5. The
4-OOH-CP concentration-survival curves of three human
tumour cell lines are depicted in panel a. These cell lines have
vastly different sensitivities to 4-OOH-CP. This diverse range
of sensitivity can be accurately predicted by the GSH assay
(panel b). The concentration of 4-OOH-CP needed to pro-
duce GSH depletion to -40% (Figure 5b) of initial level for
each cell line was closely related to the corresponding IC99
value (Figure Sa and Table II).
Discussion
The present study demonstrated that an assay technique
based on the measurement of the degree of cellular GSH
depletion immediately following 4-OOH-CP treatment can
effectively and rapidly predict tumour response to 4-OOH-
CP. Significant drug cytotoxicity was always accompanied by
significant depletion of GSH content and vice versa (Figure
4). For example, a dose of 4-OOH-CP that depletes GSH to
40% of initial level indicates clonogenic survival of approx-
imately 1%. Therefore a cell type in which GSH content can
be depleted to 40% or less with the maximally achievable
concentration of 4-OOH-CP in patients (20-25 ltM) (Sladek
et al., 1984) may be considered 'sensitive'.
One of the important features of this assay is the ease and
reliability with which a complete dose-response curve can be
obtained for each tumour type (Figure 5). It is envisaged that
the dose-response data obtained may ultimately aid in deter-TUMOUR SENSITIVITY TO CYCLOPHOSPHAMIDE 221
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Figure 3 a The effects of 4-OOH-CP treatment on cellular GSH
content in the MLS human ovarian cancer cell line. Data shown
are the average of three repeat experiments. b The concentration-
cytotoxicity relationship of 4-OOH-CP for the MLS cell line.
Results are from three independent experiments. All data points
are means ± 1 s.d.
mining the dose of cyclophosphamide needed to achieve a
desired tumour response. This feature of the assay is of
particular value because cyclophosphamide, with appropriate
autologous bone marrow support, may be administered up to
15-fold above the conventional dosage (Smith et al., 1983).
With these escalated doses of cyclophosphamide, tumour
response may become evident even when none was apparent
at conventional dosages (Frei & Canellos, 1980; Antman et
al., 1987). Other important advantages of this GSH-targeted
assay for clinical application include the following. (1)
Cytotoxicity level greater than 1% clonogenic cell survival
can be predicted. (2) Test results will be available within the
same day. (3) Single cell suspensions are not a necessary
requirement. (4) Micro-organism contamination, a frequently
encountered difficulty in most predictive assays, is not a
problem because of the short duration of the assay. (5) It is
not necessary to establish a clonogenic cell survival assay
which may prove problematic with human tumour samples.
The effectiveness of the GSH-targeted assay in predicting
tumour cell sensitivity to 4-OOH-CP is founded on the
special interaction between the active metabolites of cyclo-
phosphamide and GSH (Hohorst et al., 1976; Kwon et al.,
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lines of diverse chemosensitivity to 4-OOH-CP. Cells were
exposed to 4-OOH-CP for 3 h as described in Materials and
methods. b The effects of 4-OOH-CP treatment for 3 h on the
cellular GSH content of the same three cell lines.
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1987). Evidence has been obtained demonstrating that the
amount of the ultimate active metabolites, phosphoramide
mustard (PM) and acrolein (AC), formed intracellularly from
the spontaneous breakdown of 4-hydroxycyclophosphamide
(4-OH-CP), is dependent on the extent ofinteraction between
GSH and the toxic metabolites. GSH, by reacting with the
intermediate metabolite aldophosphamide (AP), stabilises it
from spontaneous breakdown to PM, thus minimising its
cytotoxic effects. In a sensitive cell type, the GSH stabilising
step is inadequate, leading to increased formation of AC and
PM. The former can in turn further deplete cellular GSH.
Consequently, a catastrophic cycle of GSH depletion, AP
destabilisation and toxic metabolites formation is rapidly put
into effect. We believe it is this mechanism that has rendered
the cellular GSH status as such a sensitive indicator of
tumour sensitivity to 4-OOH-CP.
Finally, a definite correlation between the steady-state cel-
lular GSH content of tumour cell lines in vitro and their
chemosensitivities to 4-OOH-CP (Figure 2) was also demon-
strated. The considerable scatter in the data, however, does
not allow the use of steady-state GSH content per se to
precisely predict for sensitivity to 4-OOH-CP. Nevertheless,
these data provide strong evidence that GSH plays a critical
role in determining the success or failure of chemotherapy
with cyclophosphamide.
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